Medpace (MEDP) earnings

Medpace Holdings, Inc.· Health Care

Results to: Sep 2026
Latest analysed call: Sep 2026 (Q3 FY26)
Balance sheet to: Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Medpace earnings: last reported Thu, 22 Oct 2026, for the quarter ended Sep 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	716 $ million	+8.5% YoY	Quarterly, as filed	Quarter to Sep 2026	Revenue from operations as filed.
Operating margin	23.1 %	+1.6 pts YoY	Operating profit / revenue	Quarter to Sep 2026	For the quarter; a change is in percentage points.
Net profit	137 $ million	+23.7% YoY	Quarterly, as filed	Quarter to Sep 2026	Profit after tax as filed.

Source: Inve data from filed results (SEC filings) · to Sep 2026

Price

$669.2 +2.33% · +$15.24

Last close Oct 23, 2026 · US · USD · Source: Inve

Performance +22.4% 1Y

1Y: $546.74 on 22 Oct 2025 → $669.2. High $669.2 (23 Oct 2026), low $393.42 (23 Apr 2026).

Previous close: $653.96
52-week range: $393.42 – $669.2
One year: +12.17%

Overview

Symbol: MEDP
Sector: Health Care
Exchange: US
Currency: USD

Financials

What the filings say

Net profit, year on year: +24% (quarter to sep 2026 against sep 2025).

In $ million. Oldest period first.

Line item	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Sales	537	559	603	660	708	707	707	716
Expenses	411	445	477	518	555	565	561	550
Operating profit	125	114	126	142	153	142	147	166
Operating margin	23.4%	20.3%	20.9%	21.5%	21.6%	20.0%	20.8%	23.1%
Other income	9	5	-2	1	4	6	5	5
Profit before tax	134	118	125	143	157	148	152	171
Tax rate	12.6%	3.0%	27.5%	22.2%	13.8%	16.1%	20.0%	19.6%
Net profit	117	115	90	111	135	124	121	137
EPS ($ per share)	—	3.77	3.16	3.95	—	4.35	4.31	4.92

Source: Inve data · income statement, quarterly · to Sept 2026

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Equity capital	0	0	0	0	0	0	0	0
Reserves	-41	68	115	235	-360	-222	8	-460
Total liabilities	378	417	585	707	966	1,098	1,275	1,516
Fixed assets	52	47	85	93	110	121	124	131
Total assets	968	1,143	1,391	1,660	1,352	1,657	2,101	1,975

Source: Inve data · balance sheet · to Dec 2025

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from operations	157	202	259	263	388	433	609	713
Cash from investing	-17	-19	-31	-31	-39	-35	-28	-31
Cash from financing	-142	-74	-82	-44	-776	-183	-154	-860
Net cash flow	-3	109	146	184	-433	217	424	-172
Capital expenditure	-16	-18	-31	-28	-37	-37	-37	-31
Free cash flow	141	184	227	235	351	397	572	682

Source: Inve data · cash flow · to Dec 2025

MEDP revenue by segment

MEDP revenue by business segment, share of consolidated revenue by quarter
Segment	Q3 FY2024	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025	Q1 FY2026	Q2 FY2026	Q3 FY2026	YoY growth latest quarter
Reportable	—	100%	100%	100%	100%	100%	100%	100%	+8.5%

Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.

See how segments are shifting across companies → Segment Shift

MEDP operating KPIs by quarter

MEDP operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Mar 2026 Q1 FY26	Jun 2026 Q2 FY26	Sep 2026 Q3 FY26	Change vs prior quarter
Net book-to-bill ratio	0.88 ratio Net bookings were below the level of -- seen in Q4, but well above those in Q1 2025 with a net book-to-bill ratio of 0.88. Source: earnings call transcript	1.13 ratio Net new business awards entering backlog in the second quarter increased 28.2% from the prior year to $795.7 million, resulting in a 1.13 net book-to-bill. Source: earnings call transcript	—	+28.4%
Net new business awards	$618.4M Net new business awards entering backlog in the first quarter increased 23.7% from the prior year to $618.4 million, resulting in a 0.88 net book-to-bill. Source: earnings call transcript	$795.7M Net new business awards entering backlog in the second quarter increased 28.2% from the prior year to $795.7 million, resulting in a 1.13 net book-to-bill. Source: earnings call transcript	$873.4M Net new business awards entering backlog in the third quarter increased 10.6% from the prior year to $873.4 million. Source: earnings call transcript	+9.8%
Backlog	~$2.9B Ending backlog as of March 31, 2026, was approximately $2.9 billion, an increase of 2.9% from the prior year. Source: earnings call transcript	~$3B Ending backlog as of June 30, 2026, is approximately $3 billion an increase of 4.9% from the prior year. Source: earnings call transcript	~$3.2B Ending backlog as of September 30, 2026, was approximately $3.2 billion, an increase of 5.6% from the prior year. Source: earnings call transcript	—
Backlog conversion rate	23.3% We project that approximately $1.94 billion of backlog will convert to revenue in the next 12 months, and backlog conversion in the first quarter was 23.3% of beginning backlog. Source: earnings call transcript	24.1% Backlog conversion in the second quarter was 24.1% of beginning backlog. Source: earnings call transcript	23.8% Backlog conversion in the third quarter was 23.8% of beginning backlog. Source: earnings call transcript	-0.3 pt

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Insider filings

96 filings between Oct 27, 2025 and Oct 12, 2026.

Open market

decisions to buy or sell

Purchases

None

No insider bought shares.

Sales

$467.02M

58 sales by 9 insiders

2% filed under a 10b5-1 plan — scheduled in advance, not decided on the day

Compensation

not trading decisions

37: Option exercise — converted options into shares

Also filed: 1 gift.

Who traded

open market only

Insider	Bought	Sold	Last filing
Troendle August J.	—	$358.45M	Sep 30, 2026
GEIGER JESSE J	—	$41.11M	Mar 17, 2026
BURWIG SUSAN E	—	$28.78M	Jul 28, 2026
EWALD STEPHEN P	—	$16.48M	May 28, 2026
DAVENPORT FRED B JR	—	$7.89M	Aug 19, 2026
Kraft Robert O.	—	$6.21M	Aug 26, 2026
Brady Kevin M.	—	$3.90M	Aug 20, 2026
Carley Brian T	—	$3.04M	Aug 19, 2026

Latest filings (50)

Date	Insider	What	Shares	Value
Oct 12, 2026	BURWIG SUSAN E Exec. VP, Operations	Option exercise	3,000	$500.2K
Oct 7, 2026	BURWIG SUSAN E Exec. VP, Operations	Option exercise	2,000	$333.5K
Sep 30, 2026	McCarthy Cornelius P. III Director	Option exercise	28	—
Sep 30, 2026	Kraft Robert O. Director	Option exercise	32	—
Sep 30, 2026	Carley Brian T Director	Option exercise	36	—
Sep 30, 2026	Troendle August J. President & CEO	Sale	21,966	$13.74M
Sep 29, 2026	Troendle August J. President & CEO	Sale	26,701	$16.58M
Sep 28, 2026	Troendle August J. President & CEO	Sale	2,410	$1.49M
Sep 25, 2026	Troendle August J. President & CEO	Sale	154	$95.6K
Sep 24, 2026	Troendle August J. President & CEO	Sale	27,833	$17.29M
Sep 23, 2026	Troendle August J. President & CEO	Sale	16,083	$10.11M
Sep 22, 2026	Troendle August J. President & CEO	Sale	49,018	$30.79M
Sep 21, 2026	Troendle August J. President & CEO	Sale	21,883	$13.64M
Sep 17, 2026	Troendle August J. President & CEO	Sale	10,880	$6.75M
Sep 16, 2026	Troendle August J. President & CEO	Sale	8,770	$5.45M
Sep 15, 2026	Troendle August J. President & CEO	Sale	15,971	$9.92M
Sep 15, 2026	BURWIG SUSAN E Exec. VP, Operations	Option exercise	3,000	$500.2K
Aug 27, 2026	Troendle August J. President & CEO	Sale	650	$403.2K
Aug 26, 2026	Kraft Robert O. Director	Option exercise	3,858	$325.5K
Aug 26, 2026	Kraft Robert O. Director	Sale	3,858	$2.38M
Aug 26, 2026	Troendle August J. President & CEO	Sale	4,000	$2.48M
Aug 25, 2026	Troendle August J. President & CEO	Sale	673	$417.5K
Aug 24, 2026	Troendle August J. President & CEO	Sale	1,983	$1.23M
Aug 21, 2026	Troendle August J. President & CEO	Sale	13,995	$8.74M
Aug 20, 2026	Brady Kevin M. CFO & Treasurer	Sale	3,400	$2.13M
Aug 20, 2026	Brady Kevin M. CFO & Treasurer	Option exercise	3,400	$472.2K
Aug 20, 2026	Troendle August J. President & CEO	Sale	27,174	$16.81M
Aug 19, 2026	DAVENPORT FRED B JR Director	Option exercise	1,822	$300.0K
Aug 19, 2026	DAVENPORT FRED B JR Director	Option exercise	3,858	$325.5K
Aug 19, 2026	DAVENPORT FRED B JR Director	Option exercise	1,903	$254.8K
Aug 19, 2026	Troendle August J. President & CEO	Sale	15,609	$9.47M
Aug 19, 2026	Carley Brian T Director	Sale	5,000	$3.04M
Aug 19, 2026	DAVENPORT FRED B JR Director	Sale	7,283	$4.41M
Aug 13, 2026	Troendle August J. President & CEO	Sale	458	$275.0K
Aug 12, 2026	Troendle August J. President & CEO	Sale	11,366	$6.84M
Aug 11, 2026	McCarthy Cornelius P. III Director	Sale	1,140	$690.1K
Aug 11, 2026	Troendle August J. President & CEO	Sale	17,610	$10.66M
Aug 10, 2026	Troendle August J. President & CEO	Sale	5,534	$3.33M
Aug 7, 2026	McCarthy Cornelius P. III Director	Option exercise	3,858	$325.5K
Aug 7, 2026	McCarthy Cornelius P. III Director	Sale	795	$465.1K
Jul 28, 2026	BURWIG SUSAN E Exec. VP, Operations	Sale	7,500	$4.50M
Jul 28, 2026	Troendle August J. President & CEO	Sale	3,510	$2.11M
Jul 27, 2026	Troendle August J. President & CEO	Sale	3,728	$2.24M
Jun 30, 2026	Carley Brian T Director	Option exercise	36	—
Jun 30, 2026	McCarthy Cornelius P. III Director	Option exercise	28	—
Jun 30, 2026	Kraft Robert O. Director	Option exercise	33	—
May 28, 2026	EWALD STEPHEN P General Counsel & Corp. Secy.	Option exercise	16,349	$2.27M
May 28, 2026	EWALD STEPHEN P General Counsel & Corp. Secy.	Sale	16,349	$7.36M
Apr 24, 2026	Brady Kevin M. CFO & Treasurer	Option exercise	7,000	$972.1K
Apr 24, 2026	EWALD STEPHEN P General Counsel & Corp. Secy.	Option exercise	3,500	$486.0K

Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.

Your own record

Start an Inve Case for Medpace Holdings, Inc.

Free account. Everything above stays public.

Write why you follow Medpace Holdings, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading